http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107405307-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-22 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34 |
| filingDate | 2016-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107405307-B |
| titleOfInvention | Exenatide microsphere preparation and preparation method thereof |
| abstract | The invention discloses an exenatide microsphere preparation, which comprises the following components in percentage by weight: 3% -10% of exenatide or exenatide salt and 88% -97% of PLGA, wherein the PLGA is a mixture of low-viscosity PLGA and high-viscosity PLGA, and the weight ratio of the low-viscosity PLGA to the high-viscosity PLGA is 1: 1-9: 1. the invention also provides an O/W preparation method of the preparation. The exenatide microsphere preparation prepared by the invention has the advantages of small burst release, short release lag phase and C max /C ave Low, is beneficial to reducing the risk caused by the large fluctuation of the blood concentration when the type II diabetes is treated, and has better clinical application prospect. |
| priorityDate | 2015-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 105.